1 Circulating CD34⁺ Progenitor Cells are Predictive of All-Cause and 2 Cardiovascular Mortality and are Influenced by Physical Activity. 3 David Muggeridge^a, Jennifer Dodd^b, Mark D. Ross^b 4 5 6 ^aInstitute of Health Research & Innovation, Division of Biomedical Science, 7 University of the Highlands and Islands, Inverness, UK 8 ^bSchool of Applied Sciences, Edinburgh Napier University, Edinburgh, United 9 Kingdom 10 11 Running Title: Circulating progenitor cells predict mortality and are influenced by 12 physical activity 13 14 **Corresponding Author:** 15 Dr. Mark Ross 16 **Edinburgh Napier University** 17 School of Applied Sciences 18 Sighthill Campus 19 2.B.38 20 **EH11 4BN** 21 M.Ross@napier.ac.uk 22 0131 455 2487 23 Twitter: @mross013 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. No reuse allowed without permission.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Abstract

Background: Circulating progenitor cells (CPCs) play an important role in vascular repair and may influence cardiovascular (CV) health and longevity. Exercise is known to modulate these cells via mobilization from the bone marrow. The primary aims of this study were to evaluate the association of CPCs with mortality and explore the association between physical activity (PA) and CPCs. Design: We studied 1,751 individuals from the Framingham Offspring cohort (66 \pm 9 years [40-92 years], 54% female). CPCs (CD34⁺, CD34⁺CD133⁺, CD34⁺CD133⁺KDR⁺) were measured in participants using flow cytometry. Multivariable cox regression analyses were performed to investigate relationship of CPCs with future CV event, CV mortality and all-cause mortality. Multivariate regression analyses were performed to determine the relationship between selfreported PA and CPC counts. Results: Following adjustment for standard risk factors, there was an inverse association between CD34⁺ CPCs and all-cause mortality (hazard ratio (HR) per unit increase in CD34⁺, 0.79; 95% CI 0.64 – 0.98, *P*=0.036). CD34⁺CD133⁺ CPCs were inversely associated with CV mortality (HR 0.63, 95% CI 0.44 - 0.91, P=0.013). Associations of CD34⁺ and CD34⁺CD133⁺ with mortality were strongest in participants with pre-existing CVD. PA was associated with CD34⁺ CPCs only in CVD participants. This relationship was maintained after adjustment for confounding variables.

51 Conclusions: Higher number of CD34⁺ and CD34⁺ CD133⁺ CPCs were inversely 52 associated with all-cause and CV mortality. These associations were strongest in 53 participants already diagnosed with CVD. PA is independently associated with CD34⁺ 54 CPCs in individuals with CVD only, suggestive of greater benefit for this population 55 group. 56 57 58 **Abstract Word Count: 249** 59 60 Key Words: Stem Cells, Mortality, Cardiovascular Diseases, Exercise

Introduction

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Circulating progenitor cells (CPC) are a heterogenous group of cells which have tissue regenerative potential. A number of studies have shown that CD34⁺ CPCs and several subsets of CD34⁺ cells (such as CD34⁺CD133⁺/KDR⁺) can participate in vascular repair and growth ^{1,2}, and may be associated with vascular endothelial function³. Therefore these cells may reflect vascular integrity and have been used as vascular biomarkers of repair ⁴. Low number of these CPCs are associated with vascular dysfunction ^{3, 5} and subsequent greater cardiovascular (CV) risk ⁶. Observational studies have shown that individuals with cardiovascular disease (CVD) exhibit lower number and angiogenic function of these CPCs ⁷, reflecting reduced vascular repair capacity. Studies have demonstrated that in individuals hospitalized with heart failure 8, or with acute coronary syndromes ⁹, low number of CD34⁺ CPCs predict earlier mortality in these patients compared to patients with high numbers of CD34⁺ CPCs, which suggests impaired vascular repair capacity in those with higher mortality risk. Whilst there are no studies that have investigated the role of CD34⁺ CPCs and associated subsets in predicting clinical endpoints in a heterogenous human population, there is evidence to suggest that these CPCs are reflective of subclinical atherosclerotic risk in an apparently healthy population ⁷. Lifestyle behaviors can significantly affect CV health. Smoking, physical inactivity and obesity are associated with perturbed vascular health, leading to greater risk of mortality. Physical activity, known for its effect on improving vascular function 10

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

may do so in part via modulating CPC content and/or function. Studies investigating acute 11 and chronic exercise training 12 have demonstrated that progenitor cells can be mobilized into peripheral blood compartment in humans, where they can exert their vasoreparative functions. However, the efficacy of exercise training to promote progenitor cell number has been argued, with recent evidence demonstrating little or no change in CPC number in humans after exercise training ⁴. As yet, there is no evidence from large cohorts investigating the association between physical activity and CPCs. The primary aim of this study was to investigate the prognostic potential of CD34⁺ CPCs on all-cause and CV mortality. Furthermore, we investigated the relationship between self-reported physical activity on CPCs in a large cohort. We hypothesized that circulating CD34⁺ CPCs and subpopulations would predict mortality, and that these cells are associated with self-reported physical activity levels. Methods **Study Sample** The Framingham Heart Study (FHS) is a longitudinal community-based cohort set up in 1948 under the direction of the National Heart, Lung, and Blood Institute (NHLBI) aimed to determine factors that contribute to the onset and progression of cardiovascular disease (CVD)¹³. Subsequently, an Offspring cohort was included from 1971¹⁴. Participants (n=3,002) in the Framingham Offspring cohort who

attended the 8th examination cycle (2004-2008) were eligible for our investigation,

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

with n=1,751 included in the study due to availability of key data. Participant characteristics are shown in **Table 1**. This study complies with the Declaration of Helsinki. Ethical approval for all data collection and research purposes was granted by Boston University Medical Centre, and consent was obtained for the collection and use of the data available for secondary investigators. Edinburgh Napier University Research Ethics and Integrity Committee approved of the use of the secondary dataset for the purposes of the study. **Clinical Assessment** All participants underwent a clinical and risk factor assessment including assessment of blood pressure, height and body mass. Fasting blood samples were drawn for quantification of glucose, glycated hemoglobin (HbA1c), total cholesterol, and high density lipoprotein cholesterol (HDL-C), and triglycerides. **Quantification of Circulating Progenitor Cells** Blood samples were collected from participants in the fasted state to quantify CPC counts. Blood samples were centrifuged and the peripheral blood mononuclear cells (PBMCs) were isolated for cell phenotyping as previously described¹⁵. PBMCs were stained with anti-CD34 FITC, anti-CD133 APC and anti-KDR-PE antibodies (all BD Biosciences). CD34⁺ cells were gated for subsequent expression of CD133 and finally KDR. Total progenitor cells are defined as CD34⁺ cells, and EPCs are defined as CD34⁺CD133⁺ and CD34⁺CD133⁺KDR⁺ cells. Analysis of flow cytometry files were

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

performed using FlowJo analysis software (Treeestar, Inc.) and reviewed by investigators blinded to the identity of the participants. **Endothelial Cell Colony Forming Cells (ECFC)** In 1653 participants, PBMCs were also used to assess endothelial cell colony forming cells (ECFC). PBMCs were cultured on fibronectin-coated tissue culture plates (BD Biosciences) and cultured for 7 days. After 7 days of culture, the number of colonies in each well were counted by a single blinded individual. ECFC number was reported as average number of colonies per well up to 12 wells. **Mortality and Event Incidence** Follow up was conducted for primary end points of all-cause and cardiovascular death. Cause of death was determined through medical history, review of medical records, death certificate, interview of next of kin, and review of the National Death Index. Cardiovascular death was defined as death attributed to ischemic cause (fatal myocardial infarction, stroke). Cardiovascular event risk was only assessed in individuals with no pre-existing CVD or CV event occurring before exam 8 (n = 1467). CV event or incident CVD was assessed using the standard Framingham Heart Study criteria and included the following: new-onset angina, fatal and non-fatal MI or stroke, heart failure or intermittent claudication. **Self-Reported Physical Activity Levels**

Self-report sleep, sitting time, slight, moderate and heavy activity were determined using a physical activity questionnaire employed by the Framingham Heart Study. The numbers of hours of certain activity per week were collected. A composite score was calculated (physical activity index; PAI), for each participant by weighting a 24hr activity recall. Participants were asked to report the number of hours in a typical day spent sleeping (weighting factor [WF] = 1) and in sedentary (WF = 1.1), slight (WF = 1.5), moderate (WF = 2.4), and heavy activities (WF = 5) 16 . PAI was subsequently calculated by adding the products of the hours spent at each activity domain and their weighting factor based on the oxygen requirements for said activity 17

Statistical Analysis

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

Continuous variables were assessed for normality by assessing histograms and Q-Q plots. Data for CD34⁺, CD34⁺CD133⁺KDR⁺, CD34⁺CD133⁺ and PAI were natural log transformed and EFCFs square root Appropriate data transformations were applied where relevant prior to further analysis. All participants were categorized into tertiles for each CPC measure for event and mortality risk analyses using Kaplan-Meier curve and log-rank analyses. Subsequent Cox proportional hazards regression analyses were performed, utilizing transformed continuous data for CPC's. Cox proportional hazards regressions were performed unadjusted and adjusted for age, sex, BMI, PAI, CVD and diabetes status, smoking status. To investigate the effects of CVD status, the data set was split and analyses repeated for those free of CVD at exam 8 (n = 1467) and those with a CVD diagnosis prior to exam 8 (n = 284).

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

Proportional hazards assumptions for each of the Cox models were evaluated by plots of Schoenfeld residuals. To assess the influence of physical activity on CPC counts, linear regression analyses were performed to assess the relationship between CPC counts and PAI. A subset of physical activity, moderate + heavy activity time, was also investigated. Unadjusted and adjusted analyses are displayed. Data analyses were carried out using RStudio Team (2019, RStudio: Integrated Development for R. RStudio, Inc, Boston, MA: http://www.rstudio.com/). P-values of <0.05 were considered statistically significant. **Results Relationship between CPC Counts and Adverse Events** All-Cause Mortality Kaplan Meier curves based on tertiles of CPC counts and all-cause mortality are shown in **Figure 1 A-D**. In unadjusted Cox proportional hazard models, increases in CD34⁺ and CD34⁺CD133⁺ CPCs were significantly associated with a decrease risk of death (P < 0.001, P = 0.001; **Table 2**). Following adjustment, increases in CD34⁺ remained significantly associated with a decrease risk of death (P = 0.036). Whilst there was a trend for CD34⁺CD133⁺ on all-cause mortality this did not reach statistical significance (P = 0.07). No significant associations were observed for allcause mortality for CD34⁺CD133⁺KDR⁺ EPCs or ECFC (all P > 0.05; **Table 2**). Cardiovascular Mortality

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

Kaplan Meier curves based on tertiles of CPC counts and cardiovascular mortality are shown in **Figure 1 E-H**. In unadjusted Cox proportional hazard models, increases in CD34⁺ and CD34⁺CD133⁺ CPCs were significantly associated with a decrease risk of cardiovascular death (P = 0.008, P = 0.006; **Table 2**). Following adjustment, CD34⁺CD133⁺ CPCs were significantly associated with a decrease risk of cardiovascular death (P = 0.013). Whilst there was a trend for CD34⁺ on CVD mortality this did not reach statistical significance (P = 0.055). No other significant associations were observed for CVD mortality (all P > 0.05; **Table 2**). Relationship between CPC Counts and Adverse Events- Influence of CVD Status All-Cause Mortality Kaplan Meier curves based on tertiles of CPC counts and all-cause mortality for those free of CVD and those with CVD at exam 8 are shown in **Supplementary Figure 1**. Unadjusted and adjusted Cox proportional hazard models for CPC counts are displayed in **Table 3**. Following adjustment, increases in CD34⁺ and CD34⁺CD133⁺ CPCs were significantly associated with a decrease risk of death in those with CVD at exam 8 (P = 0.032, P = 0.003). No other significant associations were observed for all-cause mortality (all P > 0.05; **Table 3**). Cardiovascular Mortality Kaplan Meier curves based on tertiles of CPC counts and CV mortality for those free of CVD and those with CVD at exam 8 are shown in **Supplementary Figure 1.** Unadjusted and adjusted Cox proportional hazard models for CPC counts and CV mortality are displayed in **Table 3.** In unadjusted and adjusted Cox proportional

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

hazard models, increases in CD34⁺ and CD34⁺CD133⁺ CPCs were significantly associated with a decrease risk of CV mortality in the CVD present at exam 8 group (all P < 0.05, **Table 3**). No other significant associations were observed for CV mortality in either of the sub-groups (all P > 0.05). Cardiovascular Events Cox proportional hazard analysis was performed in the population free of CVD for incidence of future CV events. ECFCs were significantly associated with a decrease risk of future CV events (P = 0.046, Supplementary Table 1). There was no association between CPC counts and CV event risk for all other measures (all P >0.05). **Association of Physical Activity with CPC Counts** To assess the association between physical activity and CPC counts, both unadjusted and adjusted linear regressions were performed. In unadjusted and adjusted analyses, PAI and moderate + heavy activity hours were not associated with any CPC subset or with ECFC units. However, in the CVD group, after adjusting for confounders, both PAI and moderate + heavy activity time were positively associated with CD34⁺ CPCs, and were the only significant predictors of the number of these cells (Table 4 and **Supplementary Table 2**). Physical activity was not associated with CD34⁺CD133⁺, CD34⁺CD133⁺KDR⁺ CPCs or ECFC counts, both in univariate and multivariate analyses.

Discussion

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

Our main findings were that CD34⁺ and CD34⁺CD133⁺ CPCs were significant predictors of all-cause and CV mortality in the Framingham Offspring cohort, driven primarily by the strength of this association in individuals with CVD. Additionally, increases in self-reported physical activity is positively associated with higher CD34⁺ CPCs in our CVD cohort after adjustment for confounders, a relationship not evident in our CVD free cohort. Together these findings suggest that the observed protection of increased CD34⁺ CPCs on mortality in a diseased population is partly driven by the physical activity levels of individuals. Several small studies have investigated the prognostic potential of CPCs for predicting incident risk of all-cause and/or CV death. These studies have demonstrated that these cells can predict mortality or clinical end-points in several disease populations, for example patients with coronary artery disease ¹⁸, acute coronary syndromes ⁹, heart failure ⁸, or type 2 diabetes ¹⁹. Our data support these observations, with CD34⁺ and CD34⁺CD133⁺ CPCs predictive of all-cause and CV mortality. Interestingly, this association was absent in the CVD-free population, and driven mainly by a strong association with mortality in individuals with pre-diagnosed CVD, suggestive that the prognostic potential of these cells is much stronger in disease populations, and offers little predictive potential, if any, in apparently healthy populations. Interestingly, CD34⁺CD133⁺KDR putative EPCs showed no predictive ability for all-cause or CV death in our study.

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

In the largest study investigating the role of CPCs on incident risk prediction in a CVD cohort, Patel and colleagues¹⁸ observed that, like our study, only CD34⁺ and CD34⁺CD133⁺ CPCs were predictive of mortality. In 2 cohorts, each over 400 patients (n=905 pooled). Patel et al ¹⁸ showed that increases in both these progenitor subsets showed significant inverse association with all-cause and CV-mortality, and that CD34⁺CD133⁺KDR⁺ cells, like our data, showed no association with mortality. Our data in >1700 individuals, however, specifically shows that the associations of CD34⁺ and CD34⁺CD133⁺ with all-cause and CV mortality are driven by their prognostic strength in individuals with CVD, and not those who are CVD-free. It is likely that these cells play a more important role in cardiovascular health when the vascular system is in a state of constant damage, and that lower number of these cells in these patients reflect exhaustion of the progenitor cell pool. Both CD34⁺ and CD133⁺ progenitor cells have vascular regenerative capabilities ²⁰. These cells, reported initially to have pro-angiogenic capabilities due to the potential to differentiate into endothelial cells ¹, most probably work in a paracrine manner, through secretion of vasoactive and proangiogenic factors, such as VEGF and other pro-angiogenic cytokines ²¹. Due to their potential vasculo-reparative capacities, clinical studies have been undertaken to assess their efficacy as cellular therapies to promote recovery of blood flow in myocardial infarction and stroke studies. Clinical studies showing implantation or injection of these cell types show promise in repair of damaged myocardium in animal models ² and in some human studies ^{22, 23}, however due to the expense and research and development required to optimize this cellular therapy, other non-pharmaceutical interventions may be more effective in promoting endogenous vascular repair for clinical benefit. In addition given the reduced number

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

and function of these cells in CVD 5, and the predictive association with mortality, it is pertinent to find therapies to augment production, mobilization and function of these cells. Exercise and physical activity has the potential to mobilize these cells into the circulation as evident from acute exercise studies showing transient increases in CPCs in both healthy^{11, 24} and diseased populations ²⁵, although the response to acute exercise is somewhat diminished in CVD patients ²⁶. Long-term physical exercise and physical activity shows promise in increasing number and/or function of these CPCs ²⁷, potentially through promoting bone marrow production of progenitor cell subsets (although the origin of EPCs has been a topic of debate recently²⁸) or via reducing inflammatory or pro-apoptotic stimuli in the circulation ²⁹, thus enhancing survival of these cells in our body. Our data support the use of physical activity to promote or maintain CD34⁺ CPC number in humans. High levels of self-reported physical activity was associated with reduce risk of all-cause and CV mortality (data not shown), and interestingly was associated with higher number of CD34⁺ and CD34⁺CD133⁺ CPCs which were also associated with mortality, but only in individuals with CVD, and not in our CVD-free group. Together these findings suggest that the observed protection of increased CD34⁺ CPCs on mortality in a diseased population is partly driven by the physical activity levels of individuals. These findings maybe clinically relevant as it is supportive of exercise-based cardiac rehabilitation and suggests an area for future interventions. Whilst both acute aerobic ²⁴ and resistance exercise ¹¹ can promote progenitor cell release and improve pro-angiogenic function, long-term resistance exercise training studies are lacking and thus warranted, specifically in a CVD cohort.

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

Conclusion Our study demonstrated that CD34⁺ and CD34+CD133⁺ CPCs are predictive of mortality in a large cohort, but with more prognostic potential in individuals with CVD. Additionally, physical activity was associated with significantly greater CD34⁺ CPCs in a CVD population, with no relationship in non-CVD population. Exercise and physical activity may promote vascular health and longevity in CVD patients via promoting CD34⁺ CPC number. **Acknowledgements:** This manuscript was prepared manuscript was prepared using FRAMOFFSPRING Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the FRAMCOHORT, FRAMOFFSPRING or the NHLBI. **Funding:** the author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Edinburgh Napier University's Research Excellence Grant (M.R). D.M. is supported by the European Union's INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB). **Conflict of Interest:** The Author(s) declare(s) that there is no conflict of interest. **Authors Contributions:**

360

361

362

363

364

365

366

367

368

369

370 371

372

373

374

375

376

377

378

379

380

381

382

M.R conceived and designed the research. D.M, M.R and J.D undertook statistical analysis of the data, M.R and D.M interpreted results of the experiments, prepared figures and drafted the manuscript; all authors edited and revised the manuscript; all authors approved the final version of the manuscript. **Data Availability Statement:** The data underlying this article were provided by the National Heart, Lung and Blood Institute (NHLBI) under license / by permission. Data will be shared on request to the corresponding author with permission of the NHLBI. References Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor 1. endothelial cells for angiogenesis. Science 1997; 275: 964-967. DOI: 10.1126/science.275.5302.964. 2. Ananthaseshan S, Grudzinska MK, Bojakowski K, et al. Locally Transplanted CD34+ Bone Marrow-Derived Cells Contribute to Vascular Healing After Vascular Injury. **Transplant** 2017; 49: 1467-1476. DOI: Proc 10.1016/j.transproceed.2017.01.081. Bruyndonckx L, Hoymans VY, Frederix G, et al. Endothelial progenitor cells 3. and endothelial microparticles are independent predictors of endothelial function. J Pediatr 2014; 165: 300-305. DOI: 10.1016/j.jpeds.2014.04.015. 4. Van Craenenbroeck EM, Frederix G, Pattyn N, et al. Effects of aerobic interval training and continuous training on cellular markers of endothelial integrity in coronary

- 383 artery disease: a SAINTEX-CAD substudy. Am J Physiol Heart Circ Physiol 2015;
- 384 309: H1876-1882. DOI: 10.1152/ajpheart.00341.2015.
- 385 5. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells,
- 386 vascular function, and cardiovascular risk. New England Journal of Medicine 2003;
- 387 348: 593-600. DOI: 10.1056/NEJMoa022287.
- 388 6. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of
- 389 circulating endothelial progenitor cells predicts future cardiovascular events: proof of
- 390 concept for the clinical importance of endogenous vascular repair. Circulation 2005;
- 391 111: 2981-2987. DOI: 10.1161/circulationaha.104.504340.
- 392 Fadini GP, Coracina A, Baesso I, et al. Peripheral blood CD34+KDR+ 7.
- 393 endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-
- 394 general population. 37: aged Stroke 2006: 2277-2282. DOI:
- 395 10.1161/01.str.0000236064.19293.79.
- 396 8. Samman Tahhan A, Hammadah M, Sandesara PB, et al. Progenitor Cells and
- 397 Clinical Outcomes in Patients With Heart Failure. Circ Heart Fail 2017; 10. DOI:
- 398 10.1161/CIRCHEARTFAILURE.117.004106.
- 399 9. Samman Tahhan AS, Hammadah M, Raad M, et al. Progenitor Cells and
- 400 Clinical Outcomes in Patients with Acute Coronary Syndromes. Circulation Research
- 401 2018. DOI: 10.1161/circresaha.118.312821.

- 402 10. Seals DR, Nagy EE and Moreau KL. Aerobic exercise training and vascular
- 403 function with ageing in healthy men and women. The Journal of Physiology 2019; 597:
- 404 4901-4914. DOI: 10.1113/jp277764.
- 405 11. Ross MD, Wekesa AL, Phelan JP, et al. Resistance exercise increases
- endothelial progenitor cells and angiogenic factors. Med Sci Sports Exerc 2014; 46: 16-406
- 407 23. DOI: 10.1249/MSS.0b013e3182a142da.
- 408 12. Steiner S, Niessner A, Ziegler S, et al. Endurance training increases the number
- 409 of endothelial progenitor cells in patients with cardiovascular risk and coronary artery
- disease. 410 Atherosclerosis 2005; 181: 305-310. DOI:
- 10.1016/j.atherosclerosis.2005.01.006. 411
- 412 Kannel WB and Gordan T. Evaluation of cardiovascular risk in the elderly: the 13.
- 413 Framingham study. Bulletin of the New York Academy of Medicine 1978; 54: 573-591.
- 414 14. Kannel WB, Feinleib M, McNamara P, et al. An investigation of coronary heart
- 415 disease in families: The Framingham Offspring Study. American Journal of
- Epidemiology 1979; 110: 281-290. DOI: 10.1093/oxfordjournals.aje.a112813. 416
- 417 Cheng S, Wang N, Larson MG, et al. Circulating angiogenic cell populations, 15.
- vascular function, and arterial stiffness. Atherosclerosis 2012; 220: 145-150. DOI: 418
- 419 10.1016/j.atherosclerosis.2011.10.015.

- 420 16. Kannel WB and Sorlie P. Some Health Benefits of Physical Activity: The
- 421 Framingham Study. Archives of Internal Medicine 1979; 139: 857-861. DOI:
- 422 10.1001/archinte.1979.03630450011006.
- 423 17. Wilson PWF, Paffenbarger RS, Morris JN, et al. Assessment methods for
- 424 physical activity and physical fitness in population studies: Report of a NHLBI
- 425 workshop. American Heart **Journal** 1986; 1177-1192. 111: DOI:
- 426 https://doi.org/10.1016/0002-8703(86)90022-0.
- 427 Patel RS, Li Q, Ghasemzadeh N, et al. Circulating CD34+ progenitor cells and 18.
- 428 risk of mortality in a population with coronary artery disease. Circ Res 2015; 116: 289-
- 429 297. DOI: 10.1161/CIRCRESAHA.116.304187.
- Egan CG, Fondelli C, Pierantozzi E, et al. Putative endothelial progenitor cells 430 19.
- 431 predict long-term mortality in type-2 diabetes. Endocrine 2018. DOI: 10.1007/s12020-
- 432 018-1695-0.
- 433 20. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by
- circulating human CD34+ cells identifies a population of functional endothelial 434
- 435 precursors. Blood 2000; 95: 952-958.
- 436 21. Hur J, Yoon C-H, Kim H-S, et al. Characterization of two types of endothelial
- 437 progenitor cells and their different contributions to neovasculogenesis. Arterioscler
- 438 Thromb Vasc Biol 2004; 24: 288-293. DOI: 10.1161/01.atv.0000114236.77009.06.

- 439 22. Nasseri BA, Ebell W, Dandel M, et al. Autologous CD133+ bone marrow cells
- 440 and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial.
- European Heart Journal 2014. DOI: 10.1093/eurheartj/ehu007. 441
- 442 23. Quyyumi AA, Vasquez A, Kereiakes DJ, et al. PreSERVE-AMI: A
- 443 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary
- 444 Administration of Autologous CD34+ Cells in Patients With Left Ventricular
- 445 Dysfunction Post STEMI Circulation Research 2017; 120: 324-331. DOI:
- 446 doi:10.1161/CIRCRESAHA.115.308165.
- 447 24. Nederveen JP, Baker J, Ibrahim G, et al. Hematopoietic Stem and Progenitor
- 448 Cell (HSPC) Mobilization Responses to Different Exercise Intensities in Young and
- 449 Older Adults. Journal of Science in Sport and Exercise 2020. DOI: 10.1007/s42978-
- 450 019-00050-4.
- 451 Adams V, Lenk K, Linke A, et al. Increase of circulating endothelial progenitor 25.
- 452 cells in patients with coronary artery disease after exercise-induced ischemia.
- 453 Arterioscler **Thromb** 2004; 24: 684-690. DOI: Vasc Biol
- 454 10.1161/01.ATV.0000124104.23702.a0.
- 455 26. Moazzami K, Lima BB, Hammadah M, et al. Association Between Change in
- 456 Circulating Progenitor Cells During Exercise Stress and Risk of Adverse
- 457 Cardiovascular Events in Patients With Coronary Artery Disease. JAMA Cardiology
- 458 2020; 5: 147-155. DOI: 10.1001/jamacardio.2019.4528.

- 459 27. Cavalcante SL, Lopes S, Bohn L, et al. Effects of exercise on endothelial
- 460 progenitor cells in patients with cardiovascular disease: A systematic review and meta-
- 461 analysis of randomized controlled trials. Revista Portuguesa de Cardiologia 2020.
- 462 DOI: https://doi.org/10.1016/j.repc.2019.02.016.
- 463 28. Fujisawa T, Tura-Ceide O, Hunter A, et al. Endothelial Progenitor Cells Do Not
- 464 Originate From the Bone Marrow. Circulation 2019; 140: 1524-1526. DOI:
- 465 doi:10.1161/CIRCULATIONAHA.119.042351.

- 29. 466 Cesari F, Marcucci R, Gori AM, et al. Impact of a cardiac rehabilitation program
- 467 and inflammatory state on endothelial progenitor cells in acute coronary syndrome
- 468 patients. Int J Cardiol 2013; 167: 1854-1859. DOI: 10.1016/j.ijcard.2012.04.157.

Figure legends Figure 1. Kaplan Meier Survival Curve's for the relationship between CPC tertile group and all-cause mortality (A, B, C, D) and cardiovascular mortality (E, F, G, H) (Tertile 1 = Low count, Tertile 2 = Moderate count, Tertile 3 = High count). Statistical significance was set at p < 0.05.

504 **Tables** 505 **Table 1. Participant Characteristics**

507

508

	All	CVD-free	CVD	<i>p</i> -value
	(n=1751)	(n=1467, 84%)	(n=284, 16%)	
Age (years)	66 ± 9	65 ± 9	72 ± 9	< 0.001
	[40-92]	[40-90]	[51-92]	
Female (n, %)	940, 53.7%	822, 56%	118, 41.5%	-
BMI	28.4 ± 5.3	28.2 ± 5.3	29.2 ± 5.2	0.007
$(kg \cdot m^2)$	[13.8-54.2]	[13.8-54.2]	[18.4-45.1]	
Systolic Blood	129 ± 18	129 ± 18	131 ± 19	0.070
Pressure (mmHg)	[76-204]	[76-204]	[90-198]	
Diastolic Blood	74 ± 11	75 ± 10	70 ± 11	<0.001***
Pressure (mmHg)	[34-122]	[34-122]	[40-108]	
Fasting Glucose	107.0 ± 24.1	106 ± 23	113 ± 28	<0.001***
(mg/dL)	[36-327]	[58-327]	[36-292]	
Total Cholesterol	186.0 ± 37.5	190 ± 35.6	164 ± 39.4	<0.001***
(mg/dL)	[71-322]	[96-322]	[71-289]	
HDL-Cholesterol	57.4 ± 18.2	58.8 ± 18.3	50.3 ± 15.8	<0.001***
(mg/dL)	[21-147]	[21-152]	[23-130]	
Triglycerides	118.0 ± 70.6	115 ± 67.2	133 ± 84.4	< 0.001
(mg/dL)	[30-976]	[30-976]	[40-583]	
Smokers (n,%)	206, 11.8%	170, 12%	36, 13%	
Hypertensive (n, %)	989, 56.5%	831, 57%	158, 56%	-
CD34+ CPCs	0.0873 ± 0.0492	0.0875 ± 0.0483	0.0860 ± 0.0538	0.201
(% MNCs)	[0.011-0.490]	[0.0110-0.490]	[0.0160-0.370]	
CD34+CD133+ CPCs	0.0402 ± 0.0366	0.0407 ± 0.0380	0.0375 ± 0.0286	0.290
(% MNCs)	[0.0020-0.6090]	[0.0020-0.6090]	[0.0040-0.2420]	
CD34+CD133+KDR+	0.0040 ± 0.0037	0.0040 ± 0.0037	0.0041 ± 0.0039	0.648
(% MNCs)	[0.0001-0.0470]	[0.0001-0.0470]	[0.0002-0.0261]	
ECFC (number of	43 ± 31	43 ± 31	42 ± 32	0.470
colonies)	[0-196]	[0-196]	[0-178]	

Data are mean ± SD [range]. ECFC- Endothelial Colony Forming Cells (in 1631 participants). * p < 0.05, *** p < 0.001.

Table 2. CPC Counts and risk of death for all participants

CPC Subset	Outcome	Model	No. of	HR	HR 95%	P value
			events/ No.		CI	
			at risk			
CD34 ⁺ CPCs	All-Cause Mortality	Unadjusted	326/1751	0.64	0.52 - 0.79	<0.001***
	All-Cause Mortality	Adjusteda	326/1751	0.79	0.64 - 0.98	0.036*
	CVD Mortality	Unadjusted	71/1751	0.54	0.35 - 0.85	0.008**
	C V D Wortanty	Adjusteda	71/1751	0.64	0.41 - 1.01	0.055
CD34+CD133+KDR+	All Carra Martalita	Unadjusted	326/1751	0.88	0.76 - 1.01	0.066
EPCs	All-Cause Mortality	Adjusteda	326/1751	0.93	0.80 - 1.07	0.300
	CVD Mortality	Unadjusted	71/1751	1.02	0.76 - 1.38	0.888
		Adjusteda	71/1751	1.09	0.81 - 1.47	0.579
CD34 ⁺ CD133 ⁺ CPCs	All-Cause Mortality	Unadjusted	303/1630	0.76	0.65 - 0.90	0.001**
	All-Cause Mortality	Adjusteda	303/1630	0.86	0.72 - 1.01	0.07
	CVD Mortality	Unadjusted	65/1630	0.61	0.43 - 0.87	0.006**
		Adjusteda	65/1630	0.63	0.44 - 0.91	0.013*
ECFC	All-Cause Mortality	Unadjusted	321/1653	0.97	0.92 - 1.01	0.145
	An-Cause Mortality	Adjusteda	321/1653	0.98	0.94 - 1.03	0.478
	CVD Montality	Unadjusted	71/1653	0.97	0.88 - 1.07	0.547
	CVD Mortality	Adjusteda	71/1653	1.00	0.90 – 1.10	0.932

510 HR – Hazard Ratio, CI – Confidence Intervals

511 ^aModel adjusted for age, sex, BMI, PAI, Smoking Status, Diabetes Status, Hypertension

512 and previous CVD diagnosis

513 *** P < 0.001, ** P < 0.01, * P < 0.05

Table 3. CPC Counts and risk of death for all participants split by CVD diagnosis at exam 8

CPC Subset	Outcome	Model	CVD Free at Exam 8			CVD Diagnosis by Exam 8				
			No. of events/ No.	HR	HR 95% CI	P value	No. of events/	HR	HR 95% CI	P value
			at risk				No. at risk			
CD34 ⁺ CPCs	All-Cause Mortality	Unadjusted	211/1467	0.70	0.54 - 0.91	0.008**	115/284	0.57	0.41 - 0.81	0.002**
		Adjusteda	211/1467	0.89	0.67 - 1.18	0.424	115/284	0.68	0.48 - 0.97	0.032*
	CVD Mortality	Unadjusted	34/1467	0.65	0.34 - 1.26	0.203	37/284	0.49	0.26 - 0.91	0.023*
		Adjusteda	34/1467	0.84	0.41 - 1.70	0.619	37/284	0.53	0.28 - 0.99	0.048*
CD34 ⁺ CD133 ⁺ KDR ⁺	All-Cause Mortality	Unadjusted	211/1467	0.90	0.76 - 1.08	0.258	115/284	0.85	0.68 - 1.06	0.149
EPCs		Adjusteda	211/1467	0.92	0.76 - 1.11	0.385	115/284	0.94	0.75 - 1.18	0.586
	CVD Mortality	Unadjusted	34/1467	0.86	0.56 - 1.33	0.492	37/284	1.17	0.79 - 1.72	0.442
		Adjusteda	34/1467	0.80	0.49 - 1.28	0.350	37/284	1.28	0.86 - 1.90	0.229
CD34 ⁺ CD133 ⁺ CPCs	All-Cause Mortality	Unadjusted	196/1364	0.85	0.69 - 1.04	0.11	107/266	0.61	0.46 - 0.82	0.001**
		Adjusteda	196/1364	0.99	0.80 - 1.23	0.943	107/266	0.64	0.48 - 0.86	0.003**
	CVD Mortality	Unadjusted	31/1364	0.78	0.47 - 1.30	0.344	34/266	0.45	0.27 - 0.76	0.003**
		Adjusteda	31/1364	0.86	0.50 - 1.49	0.588	34/266	0.42	0.24 - 0.72	0.002**
ECFC	All-Cause Mortality	Unadjusted	205/1391	0.96	0.91 - 1.02	0.179	116/262	0.99	0.92 - 1.07	0.782
		Adjusteda	205/1391	0.97	0.92 - 1.02	0.261	116/262	1.01	0.93 - 1.09	0.828
	CVD Mortality	Unadjusted	34/1391	1.03	0.90 - 1.19	0.655	37/262	0.93	0.82 - 1.07	0.317
		Adjusteda	34/1391	1.03	0.90 - 1.19	0.633	37/262	0.95	0.82 - 1.09	0.437

HR- Hazard Ratio, CI- Confidence Intervals

514

515

516

 a Model adjusted for age, sex, BMI, PAI, Smoking Status, Diabetes Status, Hypertension. *** P < 0.001, ** P < 0.001, * P < 0.001

Table 4. Association Between Physical Activity Index and CPC Counts

CPC Subset	Outcome	All	CVD-Free	CVD
		ß, T-value, P-Value	ß, T-value, P-Value	ß, T-value, P-Value
CD34 ⁺	Unadjusted	0.023, 0.967, 0.334	-0.013, -0.486, 0.627	0.176, 3.009, 0.003**
	Adjusteda	0.008, 0.322, 0.748	-0.021, -0.813, 0.416	0.153, 2.461, 0.014*
CD34+CD133+	Unadjusted	-0.014, -0.567, 0.571	-0.04, -1.495, 0.135	0.115, 1.893, 0.059
	Adjusted ^a	-0.022, -0.872, 0.383	-0.042, -1.574, 0.116	0.107, 1.616, 0.107
CD34 ⁺ CD133 ⁺ KDR ⁺	Unadjusted	0.022, 0.901, 0.368	0.002, 0.086, 0.932	0.108, 1.817, 0.07
	Adjusteda	0.019, 0.775, 0.439	0.005, 0.194, 0.846	0.080, 1.269, 0.205
ECFC	Unadjusted	0.005, 0.197, 0.844	-0.005, -0.201, 0.841	0.049, 0.785, 0.433
	Adjusted ^a	-0.006, -0.241, 0.809	-0.015, -0.535, 0.592	0.036, 0.537, 0.592

^aModel adjusted for age, sex, BMI, Smoking Status, Diabetes Status and Hypertension.

ECFC- Endothelial colony forming cells.

*** P < 0.001, ** P < 0.01, * P < 0.05

For "All" adjustment also includes previous CVD diagnosis

Figures

533

534




Figure 1

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

Supplementary information Data analysis Data analyses were carried out using RStudio Team (2019, RStudio Team (2019). RSt udio: Integrated Development for R. RStudio, Inc., Boston, MA: http://www.rstudio.c om/) utilising the R core package [1] and the extension packags "dplyr" for data clean ing and transformation [2], "survival" for survival analyses [3] and "ggplot2" [4].and "survminer" [5] for figure generation. [1] R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.or g/. [2] Hadley Wickham, Romain François, Lionel Henry and Kirill Müller (2020). dplyr: A Grammar of Data Manipulation. R package version 0.8.5. https://CRAN.R-project.org/package=dpl yr [3] Therneau T (2020). A Package for Survival Analysis in R. R package version 3 .1-12, <URL:https://CRAN.R-project.org/package=survival>. [4] H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016. <URL: https://ggplot2.tidyverse.org>. [5] Alboukadel Kassambara, Marcin Kosinski and Przemyslaw Biecek (2019), surv miner: Drawing Survival Curves using 'ggplot2'. R package version 0.4.6. https://CRA N.R-project.org/package=survminer

Supplementary Tables and Figures

Supplementary Table 1. CPC Counts and risk of future CV events in participants free of CVD diagnosis at exam 8

CPC Subset	Outcome	Model	No. of	HR	HR 95%	P value
			events/ No.		CI	
			at risk			
CD34 ⁺ CPCs	CVD Event	Unadjusted	191/1467	0.99	0.75 - 1.30	0.925
		Adjusted ^b	191/1467	1.18	0.88 - 1.59	0.279
CD34+CD133+KDR+ EPCs	CVD Event	Unadjusted	191/1467	1.09	0.91 - 1.31	0.372
		Adjusted ^b	191/1467	1.06	0.87 - 1.28	0.588
CD34+CD133+ CPCs	CVD Event	Unadjusted	177/1364	0.97	0.77 - 1.21	0.783
		Adjusted ^b	177/1364	1.05	0.83 - 1.33	0.688
ECFC	CVD Event	Unadjusted	187/1391	0.94	0.89 - 1.00	0.052
		Adjusted ^a	187/1391	0.94	0.88 - 1.00	0.046*

HR- Hazard Ratio, CI- Confidence Intervals.

Hypertension

*** P < 0.001, ** P < 0.01, * P < 0.05

^aModel adjusted for age, sex, BMI, PAI, Smoking Status, Diabetes Status,

588 Supplementary Table 2. Association Between Time Spent at Moderate+Heavy 589 Physical Activity and CPC Counts.

CPC Subset	Outcome	All	CVD-Free	CVD
		ß, T-value, P-Value	ß, T-value, P-Value	ß, T-value, P-Value
CD34 ⁺	Unadjusted	0.007, 0.277, 0.782	-0.027, -1.033, 0.302	0.159, 2.706, 0.007**
	Adjusteda	0.013, 0.538, 0.591	-0.014, -0.542, 0.588	0.149, 2.449, 0.015*
CD34 ⁺ CD133 ⁺	Unadjusted	-0.026, -1.053, 0.292	-0.046, -1.723, 0.085	0.078, 1.273, 0.204
	Adjusteda	-0.020, -0.819, 0.413	-0.036, -1.362, 0.173	0.069, 1.086, 0.278
CD34 ⁺ CD133 ⁺ KDR ⁺	Unadjusted	0.029, 1.207, 0.228	0.010, 0.365, 0.715	0.119, 2.016, 0.045*
	Adjusteda	0.035, 1.449, 0.148	0.019, 0.712, 0.477	0.112, 1.827, 0.069
ECFC	Unadjusted	-0.009, -0.349, 0.727	-0.014, -0.541, 0.589	0.015, 0.243, 0.809
	Adjusteda	-0.009, -0.357, 0.721	-0.013, -0.479, 0.632	0.006, 0.096, 0.924

^aModel adjusted for age, sex, BMI, Smoking Status, Diabetes Status and Hypertension.

590


594

⁵⁹¹ For "All" adjustment also includes previous CVD diagnosis

⁵⁹² ECFC- Endothelial colony forming cells.

⁵⁹³ *** P < 0.001, ** P < 0.01, * P < 0.05

All rights reserved. No reuse allowed without permission.



Supplementary Figure 1. Kaplan Meier Survival Curve's for the relationship between mortality and CPC tertile split by participants free of CVD at exam 8 (A – H) and those diagnosed with CVD at exam 8 (I – P). Curves A- D and I – L are for all-cause mortality and curves E – H and M - P are for CV mortality. (Tertile 1 = Low count, Tertile 2 = Moderate count, Tertile 3 = High count). Statistical significance was set at p <0.05.

596597

598

599

600

601

602